These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32317400)

  • 21. Factors influencing a patient's decision regarding riluzole: an early experience.
    Rudnicki SA
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S80-1. PubMed ID: 9419060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
    Nygren I; Antonova K; Mattsson P; Askmark H
    Acta Neurol Scand; 2005 Mar; 111(3):180-4. PubMed ID: 15691287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS.
    Fávero FM; Voos MC; Castro I; Caromano FA; Oliveira ASB
    Arq Neuropsiquiatr; 2017 Aug; 75(8):515-522. PubMed ID: 28813081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS.
    Geevasinga N; Menon P; Ng K; Van Den Bos M; Byth K; Kiernan MC; Vucic S
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):580-588. PubMed ID: 27249331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic concepts in Amyotrophic Lateral Sclerosis (ALS)].
    Ludolph AC
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S21. PubMed ID: 24242034
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.
    Ginsberg GM; Lev B
    Pharmacoeconomics; 1997 Nov; 12(5):578-84. PubMed ID: 10174324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.
    Conde B; Winck JC; Azevedo LF
    Neuroepidemiology; 2019; 53(1-2):73-83. PubMed ID: 31117082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riluzole.
    Gelinas DF
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Dec; 1 Suppl 4():3-4. PubMed ID: 11466957
    [No Abstract]   [Full Text] [Related]  

  • 33. Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.
    Lu H; Le WD; Xie YY; Wang XP
    Curr Neuropharmacol; 2016; 14(4):314-21. PubMed ID: 26786249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyotrophic lateral sclerosis: practical aspects of care.
    Krivickas LS; Carter GT
    J Spinal Cord Med; 2002; 25(4):274-6. PubMed ID: 12482168
    [No Abstract]   [Full Text] [Related]  

  • 35. Early symptom progression rate is related to ALS outcome: a prospective population-based study.
    Turner M; Al-Chalabi A
    Neurology; 2002 Dec; 59(12):2012-3; author reply 2013. PubMed ID: 12499513
    [No Abstract]   [Full Text] [Related]  

  • 36. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Slowing down ALS--is this good or bad?
    Munsat TL
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2 Suppl 1():S19-22. PubMed ID: 11465919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Riluzole as a treatment for amyotrophic lateral sclerosis].
    Borrás-Blasco J; Plaza-Macías I; Navarro-Ruiz A; Perís-Martí J; Antón-Cano A
    Rev Neurol; 1998 Dec; 27(160):1021-7. PubMed ID: 9951030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.